Avalo Therapeutics Inc (NAS:AVTX)

$ 11.63 0.14 (1.22%) Market Cap: 12.03 Mil Enterprise Value: -85.98 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 46/100

Avalo Therapeutics Inc Annual Shareholders Meeting Transcript
Dec 20, 2023
Avalo Therapeutics Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Avalo Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
Avalo Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Avalo Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 14, 2022
Avalo Therapeutics Inc at Jefferies Next Generation IBD Therapeutics Summit (Virtual) - Pre-recorded Presentation Transcript
Oct 19, 2021
Cerecor Inc Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients - Corporate Call Transcript
Jul 26, 2021
Aytu BioScience Inc Acquires Prescription Product Portfolio from Cerecor Inc - M&A Call Transcript
Oct 14, 2019

Avalo Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 13, 2023 / 05:20PM GMT

Release Date Price: $573.6 (-2.85%)

Transcript

Leland Gershell

Oppenheimer & Co. Inc. - Analyst

Hello, everyone, and welcome back to another session here at Oppenheimer's 33rd Annual Healthcare Conference. I'd like to have with us Avalo Therapeutics presenting at our next session, and on behalf of Avalo, we have the company's CEO, Dr. Garry Neil, who will lead us through the business plan and the story.

And if you have any questions at the end of the call, we will only have a few minutes, and I'll be happy to ask those on your behalf. Please submit those through the Zoom Q&A function, or e-mail me at [email protected]. And with that, I'll hand the podium over to Gary.

Garry Neil

Avalo Therapeutics, Inc. - Chairman of the Board & CEO

Thanks very much, Leland, and delighted to be here this afternoon. Hello, everybody. Can I have the first, please, [Jen]? Hi. I will be, of course, referencing forward-looking statements as detailed in this disclaimer slide, which I will go through in detail, pretty standard.

Next slide. Avalo Therapeutics, our ticker symbol is AVTX on

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.